

Supporting Information

Novel deazaflavin analogues potently inhibited tyrosyl DNA phosphodiesterase 2 (TDP2) and strongly sensitized cancer cells toward treatment with topoisomerase II (TOP2) poison etoposide

Jayakanth Kankanala^{a,#}, Carlos J. A. Ribeiro^{a,#}, Evgeny Kiselev^b, Azhar Ravji^b, Jessica Williams^a, Jiashu Xie^a, Hideki Aihara^c, Yves Pommier^b and Zhengqiang Wang^{a,}*

a) Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, United States.

b) Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.

c) Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States.

** corresponding author*

Email address: wangx472@umn.edu (Z. Wang)

These authors contributed equally to this work

| | |
|--|--------|
| Docking poses of 11a and 11e | S2 |
| DT40 cell sensitization curves | S3 |
| Synthesis of intermediates | S4—15 |
| NMR spectra of final compounds | S16—45 |





Figure S1. Molecular modeling of **11a** and **11e** and docking scores. (A) Predicted binding mode of **11a** within the catalytic domain of humanized mouse TDP2 (PDB code: 5J42). (B) Predicted binding mode of **11e** within the catalytic domain of humanized mouse TDP2 (PDB code: 5J42). Key residues are highlighted in green sticks. H-bond interactions are depicted as black dotted lines. Cation- π interaction is represented as double headed arrow in black. Water molecule and magnesium ion were represented as red and blue non-bonded sphere. All the residue numberings are based on the human TDP2. (C) Docking scores of selected TDP2 inhibitors using Glide.






■ No Etoposide

▲ 0.1 μM Etoposide


▼ 0.15 μM Etoposide

General procedure for the synthesis of 6-amination derivatives **15**, **25**, and **30**.




To a suspension of 6-chlorouracil **13** or **29** (0.50 g, 1.0 eq) and aniline derivative **14**, **20** or **21** (1.3 eq) in ethanol (5 mL) was irradiated at 150 °C for 30 minutes under microwave conditions. The reaction mixture was cooled and the precipitated solid was filtered, washed with cold methanol and ether and air dried to furnish the desired product **15**, **25** or **30**. Compounds **30c** (R' = 4-ClPh, R = *p*-NHSO₂Me), and **30d** (R' = 4-ClPh, R = *m*-NHSO₂Me) were oils and observed to slightly decompose on drying, and therefore they were taken directly to the next step after purification by column chromatography.

6-((3-Hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione (**15b**).




Compound **15b** was synthesized using 6-chlorouracil (**13**) and 3-hydroxyaniline (**14b**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.45 (s, 1H), 10.04 (s, 1H), 9.57 (s, 1H), 8.17 (s, 1H), 7.15 (t, *J* = 8.1 Hz, 1H), 6.63 – 6.59 (m, 2H), 6.54 (dd, *J* = 8.1, 1.5 Hz, 1H), 4.76 (s, 1H).

6-((4-Hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione (**15c**).




Compound **15c** was synthesized using 6-chlorouracil (**13**) and 4-hydroxyaniline (**14c**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.31 (s, 1H), 10.06 (s, 1H), 9.50 (s, 1H), 7.82 (s, 1H), 7.02 (d, $J = 8.1$ Hz, 2H), 6.77 (d, $J = 8.1$ Hz, 2H), 4.35 (s, 1H).

6-(Phenylamino)pyrimidine-2,4(1H,3H)-dione (15d).




Compound **15d** was synthesized using 6-chlorouracil (**13**) and aniline (**14d**). ^1H NMR (400 MHz, DMSO- d_6) δ 10.50 (s, 1H), 10.20 (s, 1H), 8.28 (s, 1H), 7.41 (t, 2H, $J = 7.8$ Hz), 7.15–7.23 (m, 3H), 4.70 (s, 1H).

6-((4-(Trifluoromethoxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (15e).




Compound **15e** was synthesized using 6-chlorouracil (**13**) and 4-(trifluoromethoxy)aniline (**14e**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.50 (s, 1H), 10.29 (s, 1H), 8.43 (s, 1H), 7.36 (d, $J = 8.6$ Hz, 2H), 7.33 – 7.27 (m, 2H), 4.71 (s, 1H).

6-((4-(Difluoromethoxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (15f).



Compound **15f** was synthesized using 6-chlorouracil (**13**) and 4-(difluoromethoxy)aniline (**14f**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.43 (s, 1H), 10.20 (s, 1H), 8.23 (s, 1H), 7.30 (t, $J = 78$ Hz, 1H), 7.25 – 7.22 (m, 2H), 7.19 – 7.16 (m, 2H), 4.58 (s, 1H).


6-(Benzo[d][1,3]dioxol-5-ylamino)pyrimidine-2,4(1H,3H)-dione (15g).



Compound **15g** was synthesized using 6-chlorouracil (**13**) and benzo[*d*][1,3]dioxol-5-amine (**14g**).


¹H NMR (600 MHz, DMSO-*d*₆) δ 10.36 (s, 1H), 10.12 (s, 1H), 7.98 (s, 1H), 6.91 (d, *J* = 8.2 Hz, 1H), 6.82 (d, *J* = 2.1 Hz, 1H), 6.67 (dd, *J* = 8.2, 2.1 Hz, 1H), 6.03 (s, 2H), 4.46 (s, 1H).

6-((2,2-Difluorobenzo[*d*][1,3]dioxol-5-yl)amino)pyrimidine-2,4(1H,3H)-dione (15h).




Compound **15h** was synthesized using 6-chlorouracil (**13**) and 2,2-difluorobenzo[*d*][1,3]dioxol-5-amine (**14h**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.46 (s, 1H), 10.29 (s, 1H), 8.35 (s, 1H), 7.39 (d, *J* = 8.6 Hz, 1H), 7.33 (d, *J* = 2.1 Hz, 1H), 7.02 (dd, *J* = 8.6, 2.1 Hz, 1H), 4.60 (s, 1H).

6-((4-(Benzyloxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25a).




Compound **25a** was synthesized using 6-chlorouracil (**13**) and 4-(benzyloxy)aniline (**20a**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.35 (s, 1H), 10.11 (s, 1H), 7.96 (s, 1H), 7.44 (d, *J* = 7.5 Hz, 2H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.16 – 7.11 (m, 2H), 7.05 – 6.99 (m, 2H), 5.10 (s, 2H), 4.42 (s, 1H).

6-((4-((4-Chlorobenzyl)oxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25b).




Compound **25b** was synthesized using 6-chlorouracil (**13**) and 4-((4-chlorobenzyl)oxy)aniline (**20b**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.36 (s, 1H), 10.12 (s, 1H), 7.97 (s, 1H), 7.49-7.45 (m, 4H), 7.15 (d, *J* = 8.6 Hz, 2H), 7.03 (d, *J* = 8.6 Hz, 2H), 5.10 (s, 2H), 4.43 (s, 1H).

6-((4-((4-Bromobenzyl)oxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25c).




Compound **25c** was synthesized using 6-chlorouracil (**13**) and 4-((4-bromobenzyl)oxy)aniline (**20c**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.35 (s, 1H), 10.12 (s, 1H), 7.97 (s, 1H), 7.59 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 8.3 Hz, 2H), 7.14 (d, *J* = 8.8 Hz, 2H), 7.02 (d, *J* = 8.8 Hz, 2H), 5.09 (s, 2H), 4.42 (s, 1H).

6-((4-((3-Chlorobenzyl)oxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25d).



Compound **25d** was synthesized using 6-chlorouracil (**13**) and 4-((3-chlorobenzyl)oxy)aniline (**20d**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.36 (s, 1H), 10.12 (s, 1H), 7.97 (s, 1H), 7.52 (s, 1H), 7.47 – 7.35 (m, 3H), 7.15 (d, *J* = 8.8 Hz, 2H), 7.04 (d, *J* = 8.8 Hz, 2H), 5.12 (s, 2H), 4.43 (s, 1H).


Methyl 3-((4-((2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)phenoxy)-methyl)benzoate (25e).



Compound **25e** was synthesized using 6-chlorouracil (**13**) and methyl 3-((4-aminophenoxy)methyl)benzoate (**20e**). ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.35 (s, 1H), 10.12 (s,


1H), 8.05 (s, 1H), 7.97 (s, 1H), 7.92 (d, $J = 7.8$ Hz, 1H), 7.73 (d, $J = 7.7$ Hz, 1H), 7.56 (t, $J = 7.7$ Hz, 1H), 7.15 (d, $J = 8.9$ Hz, 2H), 7.05 (d, $J = 8.9$ Hz, 2H), 5.19 (s, 2H), 4.43 (s, 1H), 3.86 (s, 3H).

3-((4-((2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)phenoxy) methyl)-benzoic acid (25f).




To a solution of **25e** (0.3 g, 1.0 eq) in ethanol (5 mL), was added NaOH (1N, 5 mL) and heated to reflux for 3 h. The reaction mixture was cooled, and ethanol was evaporated *in vacuo*. Water (5 mL) was added to it and acidified to a pH of 3-4 with 1N HCl. The resultant precipitate was filtered and washed with excess water and air dried to leave the desired acid **25f** as colorless solid (85%). ^1H NMR (600 MHz, DMSO- d_6) δ 13.02 (s, 1H), 10.36 (s, 1H), 10.16 (s, 1H), 8.07 (s, 1H), 8.03 (s, 1H), 7.90 (d, $J = 7.7$ Hz, 1H), 7.70 (d, $J = 7.5$ Hz, 1H), 7.53 (t, $J = 7.5$ Hz, 1H), 7.15 (d, $J = 8.7$ Hz, 2H), 7.05 (d, $J = 8.7$ Hz, 2H), 5.18 (s, 2H), 4.44 (s, 1H).

6-((4-Phenoxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione (25g).




Compound **25g** was synthesized using 6-chlorouracil (**13**) and 4-phenoxyaniline (**21a**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.42 (s, 1H), 10.18 (s, 1H), 8.17 (s, 1H), 7.39 (t, $J = 7.8$ Hz, 2H), 7.23 (d, $J = 8.6$ Hz, 2H), 7.14 (t, $J = 7.3$ Hz, 1H), 7.05-7.01 (m, 4H), 4.58 (s, 1H).

6-((4-(4-Chlorophenoxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25h).



Compound **25h** was synthesized using 6-chlorouracil (**13**) and 4-(4-chlorophenoxy)aniline (**21b**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.43 (s, 1H), 10.20 (s, 1H), 8.20 (s, 1H), 7.50 – 7.36 (m, 2H), 7.30 – 7.19 (m, 2H), 7.09 – 7.03 (m, 4H), 4.60 (s, 1H).


6-((4-(4-Fluorophenoxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25i).



Compound **25i** was synthesized using 6-chlorouracil (**13**) and 4-(4-fluorophenoxy)aniline (**21c**).


^1H NMR (600 MHz, DMSO- d_6) δ 10.41 (s, 1H), 10.17 (s, 1H), 8.16 (s, 1H), 7.24 – 7.20 (m, 4H), 7.09 – 7.06 (m, 2H), 7.02 – 6.99 (m, 2H), 4.56 (s, 1H).

Methyl 3-(4-((2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)phenoxy)-benzoate (25j).




Compound **25j** was synthesized using 6-chlorouracil (**13**) and methyl 3-(4-aminophenoxy)benzoate (**21d**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.43 (s, 1H), 10.22 (s, 1H), 8.22 (s, 1H), 7.72 (d, $J = 7.7$ Hz, 1H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.46 (s, 1H), 7.34 (dd, $J = 8.2, 2.5$ Hz, 1H), 7.26 (d, $J = 8.8$ Hz, 2H), 7.10 (d, $J = 8.8$ Hz, 2H), 4.61 (s, 1H), 3.83 (s, 3H).

3-(4-((2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)phenoxy)benzoic acid (25k).




Compound **25k** was synthesized using the same procedure as **25f**, using **25j** as starting material. ^1H NMR (600 MHz, DMSO- d_6) δ 13.11 (s, 1H), 10.43 (s, 1H), 10.24 (s, 1H), 8.29 (s, 1H), 7.69 (d, $J = 7.7$ Hz, 1H), 7.51 (t, $J = 7.9$ Hz, 1H), 7.46 – 7.42 (m, 1H), 7.32 – 7.28 (m, 1H), 7.26-7.22 (m, 2H), 7.11 – 7.08 (m, 2H), 4.61 (s, 1H).

6-((3-(Benzyloxy)phenyl)amino)pyrimidine-2,4(1H,3H)-dione (25l).




Compound **25i** was synthesized using 6-chlorouracil (**13**) and 3-(benzyloxy)aniline (**19f**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.46 (s, 1H), 10.13 (s, 1H), 8.23 (s, 1H), 7.44 (d, $J = 7.5$ Hz, 2H), 7.39 (t, $J = 7.5$ Hz, 2H), 7.33 (t, $J = 7.5$ Hz, 1H), 7.27 (t, $J = 8.0$ Hz, 1H), 6.82-6.80 (m, 3H), 5.09 (s, 2H), 4.73 (s, 1H).

6-((3-Phenoxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione (25m).




Compound **25m** was synthesized using 6-chlorouracil (**13**) and 3-phenoxyaniline (**21e**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.48 (s, 1H), 10.19 (s, 1H), 8.38 (s, 1H), 7.41 (t, $J = 7.8$ Hz, 2H), 7.36 (t, $J = 8.1$ Hz, 1H), 7.17 (t, $J = 7.3$ Hz, 1H), 7.06 (d, $J = 8.0$ Hz, 2H), 6.96 (d, $J = 7.8$ Hz, 1H), 6.78 (s, 1H), 6.76 (d, $J = 8.2$ Hz, 1H), 4.76 (s, 1H).

6-((4-Hydroxyphenyl)amino)-3-methylpyrimidine-2,4(1H,3H)-dione (30a).




Compound **30a** was synthesized using 6-chloro-3-methyluracil (**29b**) and 4-aminophenol (**14a**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.39 (s, 1H), 9.49 (s, 1H), 7.82 (s, 1H), 7.01 (d, $J = 8.7$ Hz, 2H), 6.77 (d, $J = 8.7$ Hz, 2H), 4.50 (s, 1H), 3.04 (s, 3H).

3-(4-chlorophenyl)-6-((4-hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione (30b).




Compound **30b** was synthesis using **29a** and 4-aminophenol (**14a**). ^1H NMR (600 MHz, DMSO- d_6) δ 10.73 (s, 1H), 9.55 (s, 1H), 8.22 (s, 1H), 7.47 (d, $J = 8.6$ Hz, 2H), 7.22 (d, $J = 8.6$ Hz, 2H), 7.07 (d, $J = 8.7$ Hz, 2H), 6.80 (d, $J = 8.7$ Hz, 2H), 4.55 (s, 1H).

General procedure for the synthesis of **19**




To a solution of *N*-Boc protected aminophenol derivative **17** (1.0 g, 1.0 eq) in DMF (15 mL) was added K_2CO_3 (2.0 eq) and stirred for 15 min followed by the addition of benzyl bromide derivative **18** (1.2 eq) over 15 min and stirred at r.t for 12 h. Water was added, and the aqueous solution was extracted with EtOAc (3 x 25 mL) followed by brine, dried over Na_2SO_4 and evaporated in vacuo. The crude compound was triturated with ether to furnish **19** which was sufficiently pure for the next step.

Tert-butyl (4-((4-chlorobenzyl)oxy)phenyl)carbamate (**19b**).




^1H NMR (600 MHz, DMSO- d_6) δ 9.13 (s, 1H), 7.49 – 7.40 (m, 4H), 7.33 (d, $J = 7.9$ Hz, 2H), 6.90 (d, $J = 9.0$ Hz, 2H), 5.03 (s, 2H), 1.45 (s, 9H).

Tert-butyl (4-((4-bromobenzyl)oxy)phenyl)carbamate (**19c**).




^1H NMR (600 MHz, DMSO- d_6) δ 9.13 (s, 1H), 7.57 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 5.02 (s, 2H), 1.45 (s, 9H).

Tert-butyl (4-((3-chlorobenzyl)oxy)phenyl)carbamate (19d).




^1H NMR (600 MHz, DMSO- d_6) δ 9.13 (s, 1H), 7.48 (s, 1H), 7.43 – 7.36 (m, 3H), 7.34 (d, J = 8.0 Hz, 2H), 6.92 – 6.89 (m, 2H), 5.05 (s, 2H), 1.45 (s, 9H).

Methyl 3-((4-((tert-butoxycarbonyl)amino)phenoxy)methyl)benzoate (19e).



^1H NMR (600 MHz, DMSO- d_6) δ 9.14 (s, 1H), 8.02 (s, 1H), 7.91 (d, J = 7.7 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.35 (d, J = 7.5 Hz, 2H), 6.92 (d, J = 9.0 Hz, 2H), 5.13 (s, 2H), 3.86 (s, 3H), 1.46 (s, 9H).

General procedure for the synthesis of 20




20

To a solution of TFA in DCM (4:1, 15 mL) was added *N*-Boc protected phenoxy aniline **19** and stirred at r.t for 6 h. The solvent was evaporated in vacuo and neutralized the solution with 2N NaOH (pH = 7 - 9) and extracted with EtOAc (2x 20 mL). The combined organic solution was washed with brine, dried over Na₂SO₄ and evaporated in vacuo. Compounds **20d** (*p*, R= 3-Cl), and


20e (*p*, R= 3-COOMe) were oils and observed to slightly decompose on drying, so they were taken to the next step without any further purification.

4-((4-Chlorobenzyl)oxy)aniline (20b).




Colorless solid, 75% yield. $^1\text{H NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 7.42-7.40 (m, 4H), 6.70 (d, $J = 8.6$ Hz, 2H), 6.49 (d, $J = 8.6$ Hz, 2H), 4.94 (s, 2H), 4.62 (s, 2H).

4-((4-Bromobenzyl)oxy)aniline (20c).




$^1\text{H NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 7.56 (d, $J = 8.2$ Hz, 2H), 7.36 (d, $J = 8.2$ Hz, 2H), 6.71 (d, $J = 8.7$ Hz, 2H), 6.50 (d, $J = 8.7$ Hz, 2H), 4.92 (s, 2H).

Synthesis of methyl 3-(4-aminophenoxy)benzoate (21d)




To a solution of **24a** (0.60 g, 2.19 mmol, 1.0 eq) in EtOAc (10 mL) was added 10% Pd/C (100 mg) and the reaction mixture was stirred at room temperature under a hydrogen environment (balloon) overnight. TLC indicated the disappearance of starting material and the product mass is confirmed by MS. The reaction mixture was filtered through celite, washed with EtOAc and dried under vacuo. The crude product was purified using CombiFlash with 0-30% EtOAc in hexane as an eluent to produce the desired product as colorless oil (0.46 g, 87%). The compound was observed to slightly decompose on drying, so it was taken to the next step without any further purification.

Synthesis of methyl 3-(4-nitrophenoxy)benzoate (24a)



To a solution of Methyl-3-hydroxybenzoate (1.29 g, 8.50 mmol, 1.2 eq) in DMF (15 mL) was added K_2CO_3 (1.96 g, 14.17 mmol, 2.0 eq) and stirred at room temperature for 15 min. 1-Fluoro-4-nitrobenzene (1.0 g, 7.09 mmol, 1.0 eq) was added and the reaction mixture was heated at 110 °C for 12 h and the TLC indicated the consumption of starting material. The reaction mixture was cooled, water (20 mL) was added and extracted with EtOAc (2 x 20 mL). The combined organic layers were extracted with water (2 x 20 mL), brine (2 x 15 mL), dried over Na_2SO_4 , evaporated solution under vacuo and the trituration of the crude compound with ether furnished the desired compound as a colorless solid (1.14 g, 59%). 1H NMR (600 MHz, $DMSO-d_6$) δ 8.40 – 8.17 (m, 2H), 7.88 (d, $J = 7.7$ Hz, 1H), 7.67-7.64 (m, 2H), 7.52 (dd, $J = 8.1, 1.8$ Hz, 1H), 7.25 – 7.12 (m, 2H), 3.86 (s, 3H).


Synthesis of 1-(4-Chlorophenyl)pyrimidine-2,4,6(1H,3H,5H)-trione (28).





To a freshly made sodium ethoxide (17.58 mmol, 1.5 eq) in 17.6 mL of anhydrous ethanol, 1-(4-chlorophenyl)urea (2.0 g, 11.72 mmol, 1.0 eq) and diethyl malonate (1.79 mL, 17.56 mmol, 1.0



eq) was added and the reaction mixture was heated at reflux overnight. The reaction mixture was cooled and solvent was removed under reduced pressure. The residue was dissolved in water, then treated with 1 N aqueous HCl to adjust the pH 4~5. The precipitate was filtered off, washed with small amount of cold methanol and diethyl ether, dried in vacuo to give compound **28** as a colorless solid in 85% yield. $^1\text{H NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 11.52 (s, 1H), 7.53 (d, $J = 8.5$ Hz, 2H), 7.26 (d, $J = 8.5$ Hz, 2H), 3.71 (s, 2H).



Synthesis of 6-Chloro-3-(4-chlorophenyl)pyrimidine-2,4(1H,3H)-dione (**29a**).





To a solution of **28** (1.50 g, 6.29 mmol, 1.0 eq) in POCl_3 (6 mL) was added BnEt_3NCl (2.86 g, 12.57 mmol, 2.0 equiv.) and the mixture was stirred at 50 °C temperature for 6 h. The reaction mixture was cool down to room temperature and then pour it onto the ice dropwise. The precipitate was filtered off, washed with excess water followed by cold ether and dried in vacuo furnished the desired compound 6-Chloro-3-(4-chlorophenyl)pyrimidine-2,4(1H,3H)-dione (**29a**) as light yellow solid in 85% yield. $^1\text{H NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 12.52 (s, 1H), 7.53 (d, $J = 8.7$ Hz, 2H), 7.31 (d, $J = 8.7$ Hz, 2H), 6.02 (s, 2H).















JK-8-229







JK-8-229-carbon CARBON_01
JK-8-229-carbon

















JK-8-163_RPT_PROTON_01
JK-8-163_RPT







JK-8-163_carbon
















JK-8-215



JK-8-215 carbon

